MED
N,N-diisopropylamine (DIPEA; 2.2 equiv) in N,N-dimethylformamide
(DMF; 5 mL) was stirred at 08C for 10 min. Then, a solution of 4-(N-
aminobutyl)amino-7-chloroquinoline (1.1 equiv) in DMF was added,
and the reaction proceeded at RT for an additional 24 h. The mix-
ture was diluted with CH2Cl2 (25 mL), and the solution was washed
with 5% aq Na2CO3 (ꢄ3). The organic layer was separated, dried
over anhyd Na2SO4, filtered and concentrated. The crude product
was purified by column chromatography (EtOAc/MeOH, 4:1 v/v) to
give the desired compound 7. Compound 8, the primaquine ana-
logue of 7c, was prepared by a similar method. Full spectrocopic
and analytical data on the synthesized compounds are given in the
Supporting Information.
Acknowledgements
The authors thank the Portuguese Foundation for Science and
Technology (FCT) for funding (PTDC/QUI-QUI/116864/2010). CT
and JRBG thank FCT for a postdoctoral grant (SFRH/BPD/62967/
2009) and Programa CiÞncia 2007, respectively
Keywords: aminoquinolines
permeability pathways · Plasmodium falciparum
· cinnamic acids · malaria ·
[1] World Malaria Report 2011, World Health Organization (WHO), ISBN
report_2011/WMR2011_noprofiles_lowres.pdf (last accessed: June 17,
2012).
[4] O. Dechy-Cabaret, F. Benoit-Vical, A. Robert, B. Meunier, ChemBioChem
[6] T. R. Herrin, J. M. Pauvlik, E. V. Schuber, A. O. Geiszler, J. Med. Chem.
[7] B. Pꢀrez, C. Teixeira, M. Figueiras, J. Gut, P. J. Rosenthal, J. R. B. Gomes, P.
Gomes, Eur. J. Med. Chem. 2012, DOI: 10.1016/j.ejmech.2012.05.022.
[8] J. Wiesner, A. Mitsch, P. Wissner, H. Jomaa, M. Schlitzer, Bioorg. Med.
[9] J. X. Kelly, M. J. Smilkstein, R. Brun, S. Wittlin, R. A. Cooper, K. D. Lane, A.
Janowsky, R. A. Johnson, R. A. Dodean, R. Winter, D. J. Hinrichs, M. K.
[10] K. Kirk, H. A. Horner, B. C. Elford, J. C. Ellory, C. I. Newbold, J. Biol. Chem.
1994, 269, 3339–3347.
[13] J. Lavrado, K. Gani, P. A. Nobre, S. A. Santos, P. Figueiredo, D. Lopes, V.
[15] K. Kirk, H. A. Horner, Biochem. J. 1995, 311 (Pt 3), 761–768.
[16] M. L. Go, M. Liu, P. Wilairat, P. J. Rosenthal, K. J. Saliba, K. Kirk, Antimi-
[17] B. S. Sisodia, A. S. Negi, M. P. Darokar, U. N. Dwivedi, S. P. Khanuja, Chem.
Biol. Drug Des. 2012, 79, 610–615.
[18] R. E. Martin, A. S. Butterworth, D. L. Gardiner, K. Kirk, J. S. McCarthy, T. S.
[20] J. Lavrado, G. G. Cabal, M. Prudencio, M. M. Mota, J. Gut, P. J. Rosenthal,
C. Diaz, R. C. Guedes, D. J. Dos Santos, E. Bichenkova, K. T. Douglas, R.
In vitro heme biocrystallization inhibition assay: The assay was per-
formed as previously described.[21,22] Briefly, test compound in
DMSO at various concentrations (0.1–1 mm) was added to a solu-
tion of hemin chloride in DMSO (50 mL, 5.2 mgmLÀ1). Assays were
performed in triplicate. Controls contained equal volumes of water
(or DMSO). Biocrystallization was initiated by the addition of ace-
tate buffer (100 mL, 0.2m, pH 4.4), and the plates were incubated at
378C for 48 h. Samples were centrifuged (SIGMA 3–30 K) at
3000 rpm for 15 min. After discarding the supernatant, the pellet
was washed with DMSO (200 mLꢄ4) and then dissolved in 0.2m aq
NaOH (200 mL). The solubilized aggregates were further diluted
with 0.1m aq NaOH (1:6), and absorbance was recorded at 405 nm
(Biotek Powerwave XS with software Gen5 1.07).
In vitro falcipain-2 inhibition assay: The assay was performed as
previously described.[23] Briefly, recombinant falcipain-2 (1 nm) was
incubated with various concentrations of test compound (taken
from 10 mm DMSO stock solutions) in sodium acetate (100 mm;
pH 5.5) and dithiothreitol (10 mm) for 30 min at room temperature
before addition of the substrate, benzoxycarbonyl-Leu-Arg-7-
amino-4-methyl-coumarin (final concentration 25 mm). Fluorescence
was continuously monitored for 30 min at room temperature in
a Labsystems Fluoroskan II spectrofluorometer, and IC50 values
were determined from plots of activity versus enzyme concentra-
tion created using GraphPad Prism software.
In vitro blood-schizontocidal activity determination: The activity was
determined using a method previous reported by us.[24] Synchron-
ized ring-stage W2 strain P. falciparum was cultured with test com-
pound at various concentrations (taken from 1000ꢄ DMSO stock
solutions) in RPMI 1640 medium containing 10% human serum or
0.5% Albumax serum substitute. After incubation for 48 h, when
control cultures contained new rings, parasites were fixed with 1%
formaldehyde in phosphate-buffered saline (PBS; pH 7.4) for 48 h
at room temperature and then labeled with YOYO-1 (1 nm; Molec-
ular Probes) in 0.1% Triton X-100 in PBS. Parasitemia was deter-
mined from dot plots (forward scatter versus fluorescence) ac-
quired on a FACSort flow cytometer using CELLQUEST software
(Becton Dickinson). Growth inhibition (IC50) was determined from
plots of parasitemia (%) against inhibitor concentration generated
using GraphPad Prism software. In each case, the curve fit present-
ed an R2 value of >0.95.
[21] R. Baelmans, E. Deharo, V. Munoz, M. Sauvain, H. Ginsburg, Exp. Parasi-
[22] A. Barazarte, G. Lobo, N. Gamboa, J. R. Rodrigues, M. V. Capparelli, A. Al-
[24] N. Vale, M. Prudencio, C. A. Marques, M. S. Collins, J. Gut, F. Nogueira, J.
Matos, P. J. Rosenthal, M. T. Cushion, V. E. do Rosario, M. M. Mota, R.
Molecular docking and molecular dynamics simulations: Compu-
tational methods were used to predict the structures and stabilities
of 7–FP-2 complexes. Additional details about these calculations
are supplied in the Supporting Information.
Received: May 17, 2012
Published online on && &&, 0000
&4
&
ꢂ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemMedChem 0000, 00, 1 – 4
ÝÝ
These are not the final page numbers!